InvestorsHub Logo
Followers 227
Posts 14532
Boards Moderated 1
Alias Born 03/29/2014

Re: exwannabe post# 232754

Tuesday, 06/11/2019 9:16:15 PM

Tuesday, June 11, 2019 9:16:15 PM

Post# of 682026
I frankly don't understand your problem then.

If they revise the SAP for an outdated criteria that doesn't work for an immunotherapy, then why do you have a problem with that? Shouldn't you instead be happy or pleased that they will be able to assess PFS under a fair set of criteria?

And if DCVax doesn't work, then it won't even matter. But if it does, then this helps to give them a fair chance at approval.

And that should help patients, and it should help all of us longs who have been horribly underwater and terribly diluted over the past 5 years.

I honestly don't understand why wouldn't you be pleased with that outcome? That the treatment have a revised SAP that will more fairly assess the primary endpoint for this trial?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News